The safety of IPI-926, a novel hedgehog pathway inhibitor, in combination with gemcitabine in patients (pts) with metastatic pancreatic cancer.

Joe Stephenson,Donald A. Richards,Brian M. Wolpin,Carlos Becerra,J. Hamm,Wells A. Messersmith,S. Devens,J. Cushing,J Goddard,T. Schmalbach,C. S. Fuchs

The safety of IPI-926, a novel hedgehog pathway inhibitor, in combination with gemcitabine in patients (pts) with metastatic pancreatic cancer.

2011

Joe Stephenson
Donald A. Richards
Brian M. Wolpin
Carlos Becerra
J. Hamm
Wells A. Messersmith
S. Devens
J. Cushing
J Goddard
T. Schmalbach
C. S. Fuchs

4114 Background: IPI-926 is a novel, selective, oral, natural product-derived small molecule that targets the Hedgehog (Hh) pathway by inhibiting Smoothened (Smo). Inhibition of Smo can repress mal...

Keywords:

Metastatic pancreatic cancer
Hedgehog signaling pathway
Gemcitabine
Internal medicine
Medicine
Oncology
Hedgehog
in patient
Small molecule
Smoothened

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations